• Shire plc, of Dublin, Ireland, said its Phase II trial of Vyvanse (lisdexamfetamine dimesylate) for adults with binge-eating disorder met its primary endpoint of significantly reducing the number of binge days per week at the two highest of three doses tested. Vyvanse is currently approved for attention-deficit hyperactivity disorder. Shire said it will work with regulatory agencies to determine a path forward for larger trials in binge-eating disorder and it will explore opportunities to identify biomarkers to aid in diagnosis.